CRISPR-Based Diagnostics Market: as amplification-free Cas-enzyme detection platforms attract strategic pharmaceutical and diagnostics-incumbent partnerships, commercialization timelines compress ahead of the regulatory precedent that would normally de-risk a novel detection chemistry, so early clinical adoption concentrates in point-of-need infectious disease testing where the regulatory bar is lower, and companies that can bridge that precedent gap first capture disproportionate share of the broader molecular diagnostics categories CRISPR chemistry could eventually reach.

The global CRISPR-based diagnostics market size was USD 487.6 Million in 2025 and is expected to register a revenue CAGR of 18.6% during the forecast period. Market revenue growth is driven by factors such as strategic partnerships between CRISPR diagnostics developers and established pharmaceutical and diagnostics-incumbent companies, the technology’s amplification-free detection speed advantage over PCR-based methods, and expanding pipeline progress toward regulatory submission for point-of-need infectious disease and sexually transmitted infection testing. The first driving factor is the wave of strategic partnerships that established diagnostics and pharmaceutical companies have formed with CRISPR diagnostics developers to accelerate commercialization. OraSure Technologies acquired Sherlock Biosciences in December 2024 specifically for its CRISPR-based chlamydia trachomatis and Neisseria gonorrhoeae self-test, which was in clinical studies and expected to be submitted to the FDA for approval by the end of 2025, illustrating how an established diagnostics company is using acquisition to acquire CRISPR chemistry rather than building it internally. The second driving factor is CRISPR-based detection’s amplification-free speed advantage, which allows results in a fraction of the time required by traditional PCR-based nucleic acid amplification testing. Sherlock Biosciences’ PROMISE trial is comparing its CRISPR-based sexually transmitted infection test against PCR, the current gold standard, in 2,500 participants, generating the clinical evidence base needed to support an eventual FDA submission for over-the-counter use. The third driving factor is expanding pipeline progress across multiple companies toward the first full FDA clearance for a CRISPR diagnostic in routine, non-emergency clinical use. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single validated Cas-enzyme detection chemistry widens its own addressable market as it gets reprogrammed for new pathogen targets, letting one already-developed detection platform capture additional infectious disease categories without rebuilding the underlying chemistry from scratch. Once a CRISPR diagnostics developer validates a Cas-enzyme detection platform for one pathogen target, reprogramming the guide RNA to detect a different target sequence requires comparatively little additional development, so the value of a validated detection platform compounds as it gets extended across a growing menu of infectious disease and STI targets. As a result, demand and revenue share are concentrating around platforms with the broadest validated target menu and the strongest strategic partnerships to fund the clinical evidence generation that regulatory submission requires, and the forecast tilts toward companies backed by established diagnostics or pharmaceutical partners rather than standalone CRISPR diagnostics startups. For instance, in 2025, Sherlock Biosciences, now operating as a subsidiary of OraSure Technologies, advanced its PROMISE trial comparing its CRISPR-based sexually transmitted infection test to PCR across 2,500 participants, one of the platform’s targets built on the same core CRISPR detection chemistry the company originally developed for infectious disease applications. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the wave of strategic partnerships and acquisitions through which established diagnostics companies are acquiring CRISPR detection chemistry rather than developing it internally. CRISPR diagnostic commercialization requires both the underlying Cas-enzyme chemistry and the regulatory, manufacturing, and commercial infrastructure to bring a product to market, and few companies possess both, so partnerships that pair chemistry developers with commercialization-ready incumbents have become the dominant path to market. OraSure Technologies acquired Sherlock Biosciences in December 2024 specifically for its CRISPR-based chlamydia trachomatis and Neisseria gonorrhoeae self-test, which was in clinical studies and expected to be submitted to the FDA for approval by the end of 2025, pairing Sherlock’s detection chemistry with OraSure’s established over-the-counter diagnostics commercialization infrastructure. The recent record shows the pace. Sherlock Biosciences’ PROMISE trial, comparing its CRISPR-based test to PCR across 2,500 participants, represents the kind of large-scale registrational evidence generation that a standalone CRISPR startup would struggle to fund independently. The effect on the market is that CRISPR diagnostics commercialization is increasingly happening inside or alongside established diagnostics companies rather than through independent CRISPR-native startups reaching the market alone. These are some of the key factors driving revenue growth of the market.

The second driver is CRISPR-Cas detection chemistry’s ability to achieve PCR-comparable sensitivity without the thermal cycling amplification step that adds time and instrument complexity to traditional molecular testing. Point-of-need testing works only if a result is available fast enough to inform an immediate clinical decision, and amplification-free CRISPR detection directly targets that speed requirement in a way that PCR-based methods structurally cannot match without additional engineering, so speed advantage and point-of-need application focus reinforce each other. Collateral cleavage activity in Cas12 and Cas13 enzymes, triggered upon binding a target sequence, produces a detectable fluorescent, lateral flow, or electrochemical signal without requiring the amplification cycling that adds turnaround time to conventional PCR testing. The effect on the market is that CRISPR diagnostics are being positioned first for applications where speed is clinically decisive, such as sexually transmitted infection testing where same-visit treatment depends on rapid results, rather than for applications where centralized laboratory turnaround time is already acceptable. These are some of the key factors driving revenue growth of the market.

“Sherlock Biosciences’ PROMISE trial is comparing its CRISPR-based sexually transmitted infection test against PCR, the current gold standard, across 2,500 participants, the scale of registrational evidence needed to support the category’s first full FDA clearance for routine clinical use.”

The third driver is the accumulation of clinical evidence across multiple companies’ CRISPR diagnostic pipelines, building toward the regulatory precedent the category currently lacks. Achieving the first full FDA clearance for a CRISPR diagnostic in routine use requires registrational-quality clinical trial data comparable to what PCR-based tests have already generated, and each company’s pipeline progress incrementally de-risks the regulatory pathway for the entire category, so individual company milestones matter beyond their direct commercial effect. Sherlock Biosciences’ CT/NG test was expected to be submitted to the FDA for approval by the end of 2025, which would represent a meaningful step toward establishing the first non-emergency-use regulatory precedent for CRISPR diagnostic technology. The effect on the market is that the entire CRISPR diagnostics category’s commercial trajectory depends disproportionately on whether any single leading developer successfully clears the regulatory pathway first. These are some of the key factors driving revenue growth of the market.

However, the CRISPR-based diagnostics market faces severe adoption constraints from regulatory pathway uncertainty, the limited precedent of FDA-cleared CRISPR diagnostic products for routine clinical use, and residual assay protocol complexity that limits true point-of-care deployment. Because no CRISPR-based diagnostic assay had received full FDA approval for routine, non-emergency clinical use as of 2025, every developer pursuing an FDA submission is establishing novel regulatory precedent rather than following a pathway with a directly comparable cleared predicate device, adding both time and approval-outcome uncertainty to commercialization timelines that investors and health system buyers must price in. Limited emergency-use precedent is a second constraint, because prior CRISPR diagnostic authorizations, including Sherlock’s and Mammoth’s COVID-19 tests, were confined to Emergency Use Authorization and restricted to high-complexity CLIA laboratories rather than over-the-counter or point-of-care settings, meaning today’s developers seeking full clearance for consumer or point-of-care use cannot lean on a closely analogous cleared device. Assay protocol complexity is the third constraint, since some CRISPR diagnostic chemistries still require multiple manual steps, including separate amplification and detection stages in certain formats, that limit their suitability for true point-of-care or over-the-counter deployment without further engineering investment, so the promised simplicity of CRISPR detection is not yet fully realised in every commercial format. These factors substantially limit CRISPR-based diagnostics market growth over the forecast period.

Based on Cas enzyme type, the global CRISPR-based diagnostics market is segmented into Cas12-based, Cas13-based, and Cas14 and emerging compact enzyme systems. Cas12-based systems hold the largest revenue share, because Cas12a underpins the most clinically advanced commercial platforms, including Mammoth Biosciences’ DETECTR technology, which suits the market’s current concentration in DNA-target infectious disease applications. Cas13-based systems remain established for RNA-target applications such as viral RNA detection, and they offer complementary target versatility, but they have not yet achieved the same commercial platform maturity as leading Cas12 systems. Cas14 and emerging compact enzyme systems are expected to register rapid revenue growth in the global CRISPR-based diagnostics market over the forecast period, driven by their smaller size enabling easier integration into miniaturised point-of-care device formats, which is why academic and early-stage commercial research continues to expand this enzyme class.

Based on application, the global CRISPR-based diagnostics market is segmented into infectious disease testing, sexually transmitted infection testing, oncology biomarker detection, and agricultural and food safety testing. Infectious disease testing holds the largest revenue share, reflecting the category’s origins in COVID-19 emergency-use diagnostics and its continued position as the application area with the most regulatory and clinical precedent, which suits the technology’s speed advantage. Sexually transmitted infection testing is expected to register the fastest revenue growth rate in the global CRISPR-based diagnostics market over the forecast period, driven by Sherlock Biosciences’ PROMISE trial and the broader push toward same-visit STI diagnosis, which is why this application has become the leading edge of CRISPR diagnostics regulatory strategy.

Based on detection format, the global CRISPR-based diagnostics market is segmented into lateral flow assay, fluorescence-based detection, and electrochemical detection formats. Lateral flow assay holds a significantly large revenue share, because it offers the simplest visual readout format compatible with point-of-care and over-the-counter use cases, which suits the market’s strategic focus on point-of-need testing applications. Electrochemical detection is expected to register rapid revenue growth in the global CRISPR-based diagnostics market over the forecast period, driven by its compatibility with miniaturised, instrument-integrated device formats, which is why academic research groups continue to publish on electrochemical CRISPR biosensor development.

Based on regional analysis, the CRISPR-based diagnostics market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the leading CRISPR diagnostics developers, including OraSure Technologies/Sherlock Biosciences and Mammoth Biosciences, and because the FDA is the regulatory agency whose eventual full clearance decision the entire category is waiting on. OraSure’s December 2024 acquisition of Sherlock Biosciences and the company’s subsequent PROMISE trial both concentrate their commercial and regulatory activity in the United States. The concentration of CRISPR diagnostics regulatory strategy in the United States also means the category’s first full clearance, whenever it occurs, is expected to happen in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. The United Kingdom, Germany, and France represent the three largest national CRISPR diagnostics markets within Europe, anchored substantially in academic and early commercial research given the category’s pre-commercial status. The region’s CE-IVD pathway under the In Vitro Diagnostic Regulation has not yet been tested by a major CRISPR diagnostic submission. The result is steady rather than rapid growth, shaped more by the category’s overall pre-commercial maturity than by regional-specific demand differences.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and South Korea represent the three largest national CRISPR diagnostics markets within the region. Substantial government-backed genomics and molecular diagnostics research investment in China is driving CRISPR diagnostics research activity from a growing academic and early commercial base, leaving room for growth as the category matures globally.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national CRISPR diagnostics markets within the region, concentrated in academic research given the category’s early commercial stage. The indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised molecular biology reagents and equipment that Latin American research laboratories depend on through 2026, slowing research infrastructure buildout.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and Israel represent the primary commercial CRISPR diagnostics research markets within the region. Israel is the most established CRISPR-related life sciences research market on the continent given its concentrated biotechnology research base, while the wider Gulf states and broader African markets are still building molecular diagnostics research capacity from scratch.